Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589033 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MAPTKMT2AMAPK1SMYD2 | |
| SCHEMBL2474781 | 0.78 | SMYD2 (0.34) | SMYD2 | |
| SCHEMBL3418237 | 0.77 | F2 (0.36) | SMYD2 | |
| SCHEMBL2474091 | 0.76 | SMYD2 (0.34) | ALDH1A1MAPTKMT2AMAPK1SMYD2 | |
| SCHEMBL16919012 | 0.72 | SMYD2 (0.32) | SMYD2 | |
| SCHEMBL2475744 | 0.71 | SMYD2 (0.34) | ALDH1A1MAPTKMT2ASMYD2RAB9A | |
| SCHEMBL3422147 | 0.70 | F10 (0.38) | — | |
| SCHEMBL28994474 | 0.69 | RAB9A (0.36) | ALDH1A1MAPTKMT2ASMYD2RAB9A | |
| SCHEMBL2473621 | 0.69 | NPC1 (0.35) | ALDH1A1MAPTKMT2AMAPK1SMYD2 | |
| SCHEMBL18222530 | 0.67 | SMYD2 (0.40) | ALDH1A1MAPTKMT2AMAPK1SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| EP-2563762-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | Bayer Intellectual Property GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| WO-2011134963-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-03 | — | — | WO | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2170877-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | Bayer HealthCare AG (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155032-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | ALDH1A1 523/4885MAPT 4772/4885KMT2A 3284/4885 |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | ALDH1A1 523/4885MAPT 4772/4885KMT2A 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.